NCT02600949 Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer Status RECRUITING Phase PHASE1
NCT02599779 A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients Status COMPLETED Phase PHASE2
NCT02599324 Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors Status COMPLETED Phase PHASE1/PHASE2
NCT02595866 Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer Status COMPLETED Phase PHASE1
NCT02589496 Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis Status COMPLETED Phase PHASE2
NCT02587962 Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors Status TERMINATED Phase PHASE1/PHASE2
NCT02586610 Trial of Chemoradiation and Pembrolizumab in Patients With Rectal Cancer Status WITHDRAWN Phase PHASE2
NCT02581982 Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer Status COMPLETED Phase PHASE2
NCT02581943 Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer Status COMPLETED Phase PHASE2
NCT02579863 Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185) Status TERMINATED Phase PHASE3
NCT02576990 Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170) Status COMPLETED Phase PHASE2
NCT02576977 Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183) Status TERMINATED Phase PHASE3
NCT02575807 Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer Status TERMINATED Phase PHASE1/PHASE2
NCT02575404 GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients Status COMPLETED Phase PHASE1
NCT02574533 Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma Status COMPLETED Phase PHASE1
NCT02565992 Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA) Status COMPLETED Phase PHASE1
NCT02564380 Study of Pembrolizumab Maintenance Following First-Line Platinum Based Chemotherapy in Patients With Metastatic Squamous - Non-Small Cell Lung Cancer (sNSCLC) Status TERMINATED Phase PHASE2